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AbstrAct
Objective To determine the frequency of biochemical 
monitoring after initiation of aldosterone antagonists(AA) 
in patients also using angiotensin-converting enzyme 
inhibitors/angiotensin receptor blockers (ACEI/ARB).
setting UK primary care.
Participants ACEI/ARB users who initiated AA between 
2004 and 2014.
Outcomes We calculated the proportions with: (1) 
biochemical monitoring ≤2 weeks post initiation of AA, 
(2) adverse biochemical values ≤2 months (potassium 
≥6 mmol/L, creatinine ≥220 µmol/L and ≥30% increase 
in creatinine from baseline) and (3) discontinuers of AA in 
those with an adverse biochemical value. We used logistic 
regression to study patient characteristics associated with 
monitoring and adverse biochemical values.
results In 10 546 initiators of AA, 3291 (31.2%) had 
a record of biochemical monitoring ≤2 weeks post 
initiation. A total of 2.0% and 2.7% of those with follow-
up monitoring within 2 months of initiation experienced 
potassium ≥6 mmol/L and creatinine ≥220 µmol/L, 
respectively, whereas 13.5% had a ≥30% increase in 
creatinine. Baseline potassium (OR 3.59, 95% CI 2.43 to 
5.32 for 5.0–5.5 mmol/L compared with <5.0 mmol/L) and 
estimated glomerular filtration rate 45-59 ml/min/1.73 m2 
(OR 2.06, 95% CI 1.26 to 3.35 compared with ≥60 ml/
min/1.73 m2) were independently predictive of potassium 
≥6 mmol/L. Women and people with diabetes had higher 
odds of ≥30% increase in creatinine.
conclusion Less than one-third of patients taking ACEI/
ARB had biochemical monitoring within 2 weeks of 




itors or angiotensin receptor blockers 
(ACEI/ARB) and aldosterone antagonists 
(AA), such as spironolactone and eplere-
none, are frequently used in combination. 
They provide reductions in morbidity and 
mortality for patients with heart failure1 and 
reductions in blood pressure for patients with 
resistant hypertension.2 However, users of 
these drugs are at risk of acute kidney injury,3 
hyperkalaemia and hyperkalaemia-associated 
mortality.4 
The occurrence of adverse events asso-
ciated with combined ACEI/ARB and AA 
use was highlighted in early 2016 in the UK 
with the publication of a drug safety notice 
from the Medicines and Healthcare products 
Regulatory Agency (MHRA). It reported on 
the increasing incidence of life-threatening 
hyperkalaemic adverse events in patients 
prescribed ACEI/ARB and spironolactone.5
To help avoid adverse events after initia-
tion of AA, biochemical parameters should 
be monitored.6 At present, the National Insti-
tute of Health and Care Excellence (NICE) 
practical guidelines for heart failure recom-
mend testing for potassium, creatinine and 
estimated glomerular filtration rate (eGFR) 
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Research
strengths and limitations of this study
 ► This is a population cohort study, based on electronic 
health records from UK primary care, examining 
whether users of renin–angiotensin system 
blockade who commence aldosterone antagonists 
(AAs) have appropriate biochemical monitoring after 
initiation of AA.
 ► The population was not restricted by indication for 
therapy.
 ► Those who were hospitalised prior to or immediately 
after initiating AA may have had missing data for test 
results in primary care data. In a sensitivity analysis, 
we used primary care data linked to hospital data 
to assess monitoring in a population that was not 
hospitalised. We found similar rates of monitoring 
and adverse events compared with the main 
analysis.
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Figure 1 Flow chart demonstrating cohort selection. 
AA, aldosterone antagonist; ACEI/ARB, angiotensin-
converting enzyme inhibitor/angiotensin receptor 
blocker; CPRD, Clinical Practice Research Datalink; ESRD, 
end-stage renal disease; HES, Hospital Episode Statistics.
after 1 week; 1, 2, 3 and 6 months; and 6 monthly there-
after, following initiation of AA in heart failure.7 These 
guidelines recommend stopping the AA if potassium is 
≥6 mmol/L and if creatinine is ≥220 µmol/L. NICE guide-
lines for hypertension state that testing for sodium, potas-
sium and renal function should occur within 1 month 
after initiation of AA and as required thereafter.8
It is not known how well these guidelines are adhered 
to in the UK. Previous evidence on blood testing during 
AA treatment in the UK is historic, restricted to one 
geographical region and did not specifically assess adher-
ence to guideline-recommended blood testing.9 Data 
from North America suggest that recommended blood 
testing occurs in less than 50% of patients.3 10 11 Poor 
monitoring of patients taking these drug combinations, 
as well as increasing use among patients at high risk of 
adverse outcomes, may help to explain the increased 
occurrence of hyperkalaemic events as reported by the 
MHRA.
Therefore, among a large, recent cohort of users of 
ACEI/ARB who initiated AA, we sought to examine 
patterns of blood testing and the occurrence of hyper-
kalaemia and renal impairment. Our aims were to deter-
mine: (1) the proportion of patients initiating an AA who 
had testing within 2 weeks of initiation, (2) the patient 
characteristics associated with testing, (3) the proportion 
of patients who had adverse biochemical values post initi-
ation of AA and the proportion that then discontinued 




The Clinical Practice Research Datalink- (CPRD) is a 
nationally representative repository of deidentified elec-
tronic medical records from primary care in the UK. It 
holds data on demographics, health-related behaviours, 
test results, diagnoses, referrals and prescriptions for 
more than 11 million people with research-quality data.12 
It is one of the largest databases of longitudinal medical 
records from primary care globally and has been exten-
sively validated.12 13
For this study, we used CPRD data linked to Hospital 
Episodes Statistics (HES). This linkage is possible for 60% 
of English practices contributing to the CPRD database. 
The HES database provides data on the primary diag-
nosis for a hospital admission, as well as other diagnoses 
and procedures carried out during that admission. The 
linkage thus provides a more complete picture of comor-
bidities, improves the accuracy of timing and, in this 
study, allowed the conduct of sensitivity analyses in those 
without hospital admissions.14
Population
We identified a cohort of patients with HES-linked 
CPRD data aged ≥18 years, who initiated ACEI/ARB 
treatment between 1 April 1997 and 31 March 2014.15 We 
identified continuous courses of ACEI/ARB therapy by 
allowing for a 90-day gap between the end date of one 
prescription and the start of the next consecutive prescrip-
tion (to allow for stockpiling and medications prescribed 
in secondary care). Among this cohort, we identified 
people who subsequently became new users of AA in the 
period 2004–2014. We chose 2004 as the study start year 
to coincide with the roll-out of the Quality and Outcomes 
Framework (QOF), a system of remuneration to general 
practitioners (GPs) which encouraged the standardisa-
tion of primary medical services. The introduction of QOF 
resulted in more recording of renal function test results 
due to the incentivisation of creatinine testing among 
people with diabetes in 2004 and the establishment of a 
practice Chronic Kidney Disease (CKD) register with the 
introduction of eGFR reporting in 2006.16
New use of AA was defined as no use of AA in the year 
prior to first prescription. We then restricted the popu-
lation to those with a record for creatinine monitoring 
in the year prior to AA initiation. We assumed that those 
with creatinine test results prior to and after AA initia-
tion were also tested for potassium. If values for potas-
sium were not present, they were treated as missing. This 
approach avoided exclusion of patients whose blood 
sample may have been haemolysed, resulting in potas-
sium value not reported. Patients with Read codes for 
end-stage renal disease and eGFR values corresponding 
with CKD stage 5 prior to cohort entry were excluded. 
Patients were eligible for follow-up until the earliest of 
death, transfer out of practice, last data collection or end 
of the study (March 2014).
covariates
We obtained information for all patients on age, gender, 
calendar time of AA initiation (2004–2006, 2007–
2009 and 2010–2014) and lifestyle factors. The closest 
records to AA initiation date were used for determining 
smoking, alcohol and body mass index status using 
existing algorithms.17 We extracted data on cardiovascular 
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comorbidities and diabetes using data from both CPRD 
and HES. We calculated baseline eGFR using the most 
recent creatinine value from CPRD data prior to AA initi-
ation and the CKD Epidemiology Collaboration equa-
tion.18 CPRD prescribing data were used to extract data 
on baseline medication use. Baseline potassium values 
were categorised as: <5, 5–5.5 and >5.5 mmol/L.
Outcomes and statistical analyses
Several guidelines recommend time periods for blood 
testing after initiation of AA (online supplementary table 
1). We assessed whether monitoring occurs in line with 
the current NICE recommendations, with some modifi-
cation. NICE practical guidelines for heart failure recom-
mend blood testing within 1 week after AA initiation.7 
However, we calculated the proportion of AA initiators 
who had blood testing within 2 weeks of AA initiation 
to accommodate the practical challenges of immediate 
follow-up testing faced in clinical practice. In additional 
analyses, we also calculated the proportion of people who 
had testing (1) within 7 days post initiation of AA, (2) 
within 1, 2, 3, 6 and 12 months post initiation of AA and 
(3) on all recommended monitoring occasions. Guide-
lines offer a framework for clinicians on how to treat 
and manage patients, but adherence to guidelines is not 
obligatory and deviations may just reflect individualised 
care. Nonetheless, using clinical guidelines to frame this 
analysis provides a series of time points against which we 
can quantify frequency of monitoring for patients using 
combinations of AA and ACEI/ARB.
We used thresholds set out by the NICE practical guide-
lines for heart failure to calculate the proportion of 
patients who had an adverse biochemical value on their 
first blood test within 2 months of initiation.7 Hyperka-
laemia was a potassium of ≥6 mmol/L, and an adverse 
creatinine value indicating renal dysfunction was defined 
as creatinine ≥220 µmol/L. We chose 2 months to accord 
with monitoring periods in previous clinical trials19 and 
also because at the outset, we expected that a majority 
of patients would have testing within this time frame. 
We then calculated the proportion of those with adverse 
biochemical values who discontinued the AA. We used 
a conservative definition of discontinuation to prevent 
misclassification of people who had blood tests at the 
beginning of a median length prescription (28 days). 
Therefore, we classified discontinuation as no further 
prescription of AA beyond 30 days after the first postiniti-
ation blood test, that is, when the end date of the course 
of AA therapy occurred before the first blood test date 
plus 30 days.
Some guidelines for initiation of AA refer to an abso-
lute level of creatinine to indicate renal dysfunction of 
concern and when stopping the AA should be consid-
ered (online supplementary table 1). However, absolute 
values of creatinine reflect substantially different levels 
of eGFR depending on the age, gender and ethnicity of 
the patient. A proportional change in creatinine or eGFR 
is recommended by the NICE guidelines for CKD to 
indicate significant change in renal function for patients 
who initiate ACEI/ARB.20 This measure is therefore clin-
ically familiar and more closely indicates changes in 
renal function that may be associated with a new drug. 
Therefore, we also calculated the number of people who 
experienced a ≥30% relative increase in creatinine from 
baseline as an adverse biochemical finding. We used the 
most recent values for creatinine within 1 year prior to 
AA initiation and creatinine values on the first blood test 
within 2 months post initiation of AA to calculate the rela-
tive change.
To assess patient level characteristics associated with 
testing within 2 weeks (vs not having testing within 
2 weeks), we used logistic regression with robust standard 
errors to adjust for correlations between patients within 
practices.10 The crude model adjusted for age and gender 
only, whereas the fully adjusted model adjusted for age, 
gender, eGFR category, cardiovascular comorbidities, 
diabetes, potassium and calendar time all meaured at 
baseline. We did not include ethnicity in fully adjusted 
models due to missing data for approximately 50% of 
the population.21 We also used logistic regression to 
assess patient characteristics associated with an adverse 
biochemical value (vs not having an adverse biochemical 
value), with adjustments for the same variables as in the 
prior model.
In a sensitivity analysis, we assessed the proportion of 
patients receiving blood tests among patients who were 
not hospitalised in the 30-day period prior to or post initi-
ation of AA. Data on laboratory tests are not available in 
the HES database, and test results may not always be sent 
from the hospital to the GP practice. Therefore, this anal-
ysis excluded patients who had blood tests as inpatients, 
which would contribute to an apparently low observed 
level of testing in primary care.
We used Stata V.14 for all analyses.22
The protocol for this study was approved by the London 
School of Hygiene and Tropical Medicine Ethics 
Committee (no 6536) and the Independent Scientific 
Advisory Committee for MHRA (no 16_025A).
results
From 466 271 continuous users of ACEI/ARB between 
1997 and March 2014, 12 291 people initiated an AA 
between 2004 and 2014 and were eligible for inclusion. 
After further exclusions, 10 546 were ultimately included 
in the cohort (figure 1). The population was 41% women 
and had a mean age of 71.8 years (SD 12.9) (table 1). 
Mean baseline serum potassium was 4.4 mmol/L (SD 
0.7). Approximately one-fifth of the population had an 
eGFR <30 ml/min/1.73 m2 (table 1). Spironolactone was 
the drug given for 9917/10 546 (94%) of those initiating 
an AA, with the remainder initiating eplerenone.
testing within 2 weeks of AA initiation
Within 2 weeks post initiation of AA, 31.2% of the cohort 
had blood testing (table 1). Approximately 64% of the 
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Table 1 Characteristics of patients taking ACEI/ARB who initiate AA in UK primary care 2004–2014, by monitoring groups
Population Monitoring ≤2 weeks No monitoring ≤2 weeks
Total number 10 546 (100) 3291 (100) 7255 (100)
Female sex 4348 (41.2) 1326 (40.3) 3022 (41.6)
Age (years)
  <50 656 (6.2) 138 (4.2) 518 (7.1)
  50–59 1188 (11.3) 314 (9.5) 874 (12.1)
  60–64 957 (9.1) 275 (8.4)  682 (9.4)
  65–69 1227 (11.6) 391 (11.9) 836 (11.5)
  70–74 1513 (14.4) 502 (15.3) 1011 (13.9)
  75–79 1708 (16.2) 552 (16.8) 1156 (15.9)
  ≥80 3297 (31.3) 1119 (34.0) 2178 (30.0)
Ethnicity
  White 4687 (44.4) 1476 (44.9) 3211 (44.3)
  South Asian 119 (1.1) 33 (1.0) 86 (1.2)
  Black 101 (1.0) 23 (0.7) 78 (1.1)
  Mixed/other 58 (0.6) 11 (0.3) 47 (0.7)
  Missing/not stated 5581 (52.9) 1748 (53.1) 3833 (52.8)
Smoking
  Non-smoker 2693 (25.5) 835 (25.4) 1858 (25.6)
  Current smoker 1505 (14.3) 405 (12.3) 1100 (15.2)
  Ex-smoker 6333 (60.1) 2047 (62.2) 4286 (59.1)
  Missing 15 (0.1) * 11 (0.2)
Body mass index (kg/m2)
  Underweight (<18.5) 191 (1.8) 69 (2.1) 122 (1.7)
  Healthy weight (18.5–24.9) 2613 (24.8) 823 (25.0) 1790 (24.7)
  Overweight (25–29.9) 3335 (31.6) 1020 (31.0) 2315 (31.9)
  Obese (≥30) 4407 (41.8) 1379 (41.9) 3028 (41.7)
  Missing * * *
Alcohol
  Non-drinker 1268 (12.0) 360 (10.9) 908 (12.5)
  Current drinker 7194 (68.2) 2308 (70.1) 4886 (67.4)
  Ex-drinker 1451 (13.8) 447 (13.6) 1004 (13.8)
  Missing 633 (6.0) 176 (5.4) 457 (6.3)
Comorbidities
  Hypertension 7928 (75.2) 2496 (75.8) 5432 (74.9)
  IHD 6042 (57.3) 1919 (58.3) 4123 (56.8)
  Heart failure 6171 (58.5) 1983 (60.3) 4188 (57.7)
  Arrhythmia 4495 (42.6) 1493 (45.4) 3002 (41.4)
  Diabetes 3252 (30.8) 1043 (31.7) 2209 (30.5)
  Peripheral arterial disease 946 (9.0) 326 (9.9) 6202 (8.6)
Medication use
  Calcium channel blocker 5043 (47.8) 1578 (48.0) 3465 (47.8)
  Beta blocker 6123 (58.1) 1976 (60.0) 4147 (57.2)
  Thiazide diuretic 4354 (41.3) 1384 (42.1) 2970 (40.9)
  Loop diuretic 7447 (70.6) 2490 (75.7) 4957 (68.3)
eGFR category (mL/min/1.73 m2)†
  ≥60 5803 (55.0) 1665 (50.6) 4138 (57.0)
Continued
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Table 2 Proportion of patients taking ACEI/ARB who initiate AA in UK primary care 2004–2014 with blood tests at several 
time points post initiation of AA















The denominator changes due to patients exiting the cohort.
AA, aldosterone antagonist; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.
Population Monitoring ≤2 weeks No monitoring ≤2 weeks
  45–59 2668 (25.3) 864 (26.3) 1805 (24.9)
  30–44 1666 (15.8) 591 (18.0) 1075 (14.8)
  15–29 409 (3.9) 171 (5.2) 237 (3.3)
Calendar time
  2004–2006 2374 (22.5) 645 (19.6) 1729 (23.8)
  2007–2009 3029 (28.7) 943 (28.7) 2086 (28.8)
  2010–2014 5143 (48.8) 173 (51.8) 3440 (47.4)
Biochemical parameters at baseline‡
  Creatinine (µmol/L) (mean (SD)) 99.1 (30.7) 102.7 (33.4) 97.4 (29.3)
  Potassium (mmol/L) (mean (SD)) 4.4 (0.7) 4.4 (0.9) 4.4 (0.6)
Potassium (mmol/L)
  <5.0 8955 (84.9) 2779 (84.4) 6176 (85.1)
  5.0–5.5 1136 (10.8) 367 (11.2) 769 (10.6)
  >5.5 252 (2.4) 78 (2.4) 174 (2.4)
  Missing 203 (1.9) 67 (2.0) 136 (1.9)
Data shown are column number (%), except where mean (SD) is indicated.
*Refers to negligible.
†Calculated from most recent creatinine measurement within 12 months before AA initiation. 
‡Baseline biochemical parameters were the values closest to AA initiation in the preceding year.
AA, aldosterone antagonist; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; eGFR, estimated 
glomerular filtration rate; IHD, ischaemic heart disease.
Table 1 Continued 
population had testing within 2 months of initiation, 
whereas 95% had blood tests within 1 year (table 2). We 
conducted a sensitivity analysis among the 5787 indi-
viduals not admitted to hospital within 30 days prior 
or post initiation of AA (54.9% of the whole cohort). 
Among these patients, a similar proportion (32.7%) had 
follow-up monitoring within 2 weeks (online supplemen-
tary table 2). In the main population, the proportion of 
people having six tests within a year (roughly equating 
to optimal guideline-recommended testing within 7 days 
and 1, 2, 3, 6 and 12 months) testing was approximately 
1%.
Factors associated with testing within 2 weeks of AA initiation
Women and younger patients had lower odds for blood 
testing within 2 weeks of AA initiation (table 3). Those 
initiating AA after 2007 had higher odds of blood testing 
compared with patients initiating in 2004–2006. Those 
with high baseline potassium values did not have higher 
odds for receiving blood testing. No substantial differ-
ences were seen when the analysis was restricted to 
non-hospitalised patients although the increased odds 
of testing among patients with reduced baseline renal 
function was reduced, suggesting that there were dispro-
portionate admissions among this group (online supple-
mentary table 3).
Adverse biochemical values
Of those with follow-up monitoring within 2 months of 
AA initiation (n=6520), 2.0% had hyperkalaemia, 2.7% 
a creatinine ≥220 µmol/L and 13.5% a ≥30% increase 
in creatinine from baseline, on their first blood test 
(table 4). Of those with creatinine ≥220 µmol/L, 29 
people (16%) had creatinine ≥220 µmol/L at base-
line. Approximately half of patients with hyperkalaemia 
discontinued AA within 30 days of the blood test (table 4). 
Less than one-third of those with a ≥30% increase in 
creatinine discontinued AA, compared with 43% of 
those with a postinitiation creatinine ≥220 µmol/L. 
Among non-hospitalised patients, the proportions with 
adverse biochemical values were lower, whereas the 
proportion of people discontinuing the AA with each 
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Table 3 Association between patient characteristics and 
biochemical monitoring within 2 weeks post-initiation of AA
OR (95% CI)
Age and sex adjusted Fully adjusted
Male Ref Ref
Female 0.90 (0.83 to 0.98) 0.90 (0.82 to 0.98)
Age (years)
  <50 0.54 (0.43 to 0.67) 0.58 (0.46 to 0.73)
  50–59 0.72 (0.61 to 0.84) 0.78 (0.66 to 0.91)
  60–64 0.81 (0.68 to 0.96) 0.86 (0.72 to 1.03)
  65–69 0.94 (0.81 to 1.09) 0.96 (0.83 to 1.12)
  70–75 Ref Ref
  76–79 0.90 (0.83 to 0.98) 0.95 (0.82 to 1.10)
  ≥80 1.05 (0.92 to 1.20) 0.97 (0.85 to 1.11)
eGFR category (mL/min/1.73 m2)
  ≥60 Ref Ref
  45–59 1.10 (0.99 to 1.23) 1.13 (1.01 to 1.27)
  30–44 1.25 (1.10 to 1.42) 1.29 (1.14 to 1.46)
  15–29 1.65 (1.33 to 2.06) 1.74 (1.40 to 2.16)
Comorbidities
  Hypertension 1.03 (0.93 to 1.13) 0.98 (0.88 to 1.09)
  IHD 1.00 (0.92 to 1.09) 0.98 (0.89 to 1.07)
  Heart failure 1.05 (0.96 to 1.15) 1.01 (0.92 to 1.11)
  Arrhythmia 1.09 (1.00 to 1.19) 1.07 (0.98 to 1.18)
  Diabetes 1.06 (0.97 to 1.16) 1.05 (0.95 to 1.15)
  Peripheral arterial 
disease
1.12 (0.98 to 1.27) 1.08 (0.93 to 1.24)
Calendar time
  2004–2006 Ref Ref
  2007–2009 1.22 (1.07 to 1.38) 1.21 (1.07 to 1.38)
  2010–2014 1.34 (1.17 to 1.53) 1.35 (1.18 to 1.55)
Baseline potassium (mmol/L)
  <5.0 Ref Ref
  5.0–5.5 1.05 (0.91 to 1.20) 0.98 (0.86 to 1.12)
  >5.5 0.98 (0.73 to 1.30) 0.90 (0.68 to 1.20)
Fully adjusted: adjusted for age, gender, eGFR category, 
hypertension, heart failure, ischaemic heart disease, arrhythmias, 
diabetes, peripheral arterial disease, baseline potassium and 
calendar time. Further adjustment for lifestyle covariates made 
marginal difference to all results, thus these variables are not 
included in models shown.
AA, aldosterone antagonist; eGFR, estimated glomerular filtration 
rate; IHD, ischaemic heart disease.
Table 4 Proportion with adverse biochemical values on testing within 2 months post initiation of AA and number subsequently 
discontinuing AA
Hyperkalaemia (≥6 mmol/L)* Creatinine ≥220 µmol/L ≥30% increase in creatinine
Number with adverse biochemical values† 128/6373 (2.0%) 177/6520 (2.7%) 877/6520 (13.5%)
Number discontinuing AA‡ 68/128 (53.1%) 76/177 (42.9%) 251/877 (28.6%)
*Missing data for 147 people (2.3%) for first follow-up potassium value.
†Serum potassium and creatinine values on first blood test within 2 months of AA initiation.
‡Discontinuation defined as no further prescriptions of AA after blood test plus 30 days.
AA, aldosterone antagonist.
adverse biochemical value was similar (online supple-
mentary table 4).
Factors associated with adverse biochemical values
In fully adjusted logistic regression models, base-
line eGFR categories <60 ml/min/1.73 m2 and potas-
sium ≥5 mmol/L were independently associated with 
hyperkalaemia (table 5). Women had lower odds than 
men for a postinitiation creatinine ≥220 µmol/L but 
had a higher odds of a ≥30% increase in creatinine. In 
sensitivity analyses of the non-hospitalised cohort, similar 
associations between age and sex and the occurrence of 
adverse biochemical values were observed (online supple-
mentary table 5).
dIscussIOn
In this cohort study of 10 546 users of ACEI/ARB, less than 
a third had follow-up blood testing within 2 weeks of AA 
initiation. Less than two-thirds had blood testing within 
2 months, and of these, 2% developed severe hyperka-
laemia, and a similar proportion developed an absolute 
value of creatinine at which some guidelines recommend 
that AA cessation is considered. In the same time frame, 
13.5% of the cohort developed a ≥30% increase in serum 
creatinine from baseline.
strengths and weaknesses
We used a linked primary and secondary care dataset to 
ensure complete information on comorbid diagnoses and 
to allow sensitivity analyses for those without hospital admis-
sions. These data had high levels of completeness for baseline 
renal function and comorbidities allowing the majority of 
ACEI/ARB users initiating AA to be included in the cohort. 
A limitation of our study was that we could only examine 
adverse biochemical values for those who had a record 
of subsequent blood testing in primary care. The risk of 
adverse values may have been different in patients who were 
not tested or were tested in secondary care. Lack of access to 
blood test results from secondary care could have created a 
bias towards missing data among the sickest patients and an 
underestimation of the rate of adverse biochemical values. 
However, restricting the analysis to individuals without any 
record of a hospitalisation in the 30-day period prior to and 
after AA initiation did not substantially change our results. A 
further limitation is that for quantifying baseline renal func-
tion, we could not include an indicator for Afro-Caribbean 
ethnicity in the eGFR calculation. However, we expect the 
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Table 5 Associations between patient characteristics and adverse biochemical values after AA initiation
OR (95% CI)
Hyperkalaemia*† (≥6 mmol/L) Creatinine*≥220 µmol/L ≥30% increase in creatinine*
Female 1.04 (0.70 to 1.54) 0.34 (0.23 to 0.51) 1.47 (1.25 to 1.73)
Age (years)
  <50 0.15 (0.02 to 1.08) 0.96 (0.32 to 2.84) 0.34 (0.21 to 0.55)
  50–59 0.29 (0.10 to 0.86) 0.80 (0.32 to 2.84) 0.45 (0.32 to 0.65)
  60–64 0.60 (0.28 to 1.31) 1.17 (0.53 to 2.56) 0.69 (0.49 to 0.96)
  65–69 0.83 (0.43 to 1.59) 0.36 (0.16 to 0.83) 0.64 (0.49 to 0.85)
  70–75 Ref Ref Ref
  76–79 0.75 (0.43 to 1.33) 0.71 (0.42 to 1.20) 0.94 (0.75 to 1.18)
  80+ 0.69 (0.40 to 1.19) 0.50 (0.30 to 0.83) 1.10 (0.87 to 1.39)
eGFR category (mL/min/1.73 m2)
  ≥60 Ref Ref Ref
  45–59 2.06 (1.26 to 3.35) 2.80 (1.22 to 6.39) 0.81 (0.66 to 0.99)
  30–44 2.32 (1.31 to 4.11) 20.83 (9.73 to 44.58) 0.82 (0.67 to 1.00)
  15–29 3.62 (1.60 to 8.22) 248.0 (117.2 to 524.7) 1.01 (0.72 to 1.40)
Comorbidities
  Hypertension 1.27 (0.76 to 2.14) 0.93 (0.61 to 1.41) 1.18 (0.98 to 1.41)
  IHD 0.67 (0.45 to 1.00) 0.60 (0.43 to 0.85) 0.95 (0.82 to 1.11)
  Heart failure 0.77 (0.53 to 1.14) 0.97 (0.67 to 1.41) 1.12 (0.96 to 1.31)
  Arrhythmia 1.00 (0.68 to 1.46) 0.81 (0.57 to 1.15) 1.11 (0.96 to 1.28)
  Diabetes 1.21 (0.83 to 1.76) 1.11 (0.80 to 1.55) 1.18 (1.01 to 1.38)
  Peripheral arterial disease 0.82 (0.44 to 1.51) 1.04 (0.64 to 1.68) 1.09 (0.85 to 1.40)
Calendar time
  2004–2006 Ref Ref Ref
  2007–2009 1.14 (0.65 to 2.01) 1.36 (0.84 to 2.22) 0.97 (0.80 to 1.18)
  2010–2014 1.08 (0.64 to 1.83) 0.93 (0.58 to 1.51) 0.95 (0.78 to 1.15)
Baseline potassium (mmol/L)
  <5.0 Ref n/a n/a
  5.0–5.5 3.59 (2.43 to 5.32)
  >5.5 3.29 (1.57 to 6.88)
Only fully adjusted model is shown for clarity. Adjusted for age, gender, eGFR category, hypertension, heart failure, ischaemic heart disease, 
arrhythmias, diabetes, peripheral arterial disease, baseline potassium (hyperkalaemia model only) and calendar time. Further adjustment for 
lifestyle covariates made marginal difference to all results and is not included.
n=6520 except †missing data for 147 people for first follow-up potassium value.
*Adverse serum potassium and creatinine values on first blood test within 2 months of AA initiation.
AA, aldosterone antagonist; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart disease.
impact of this to be small given that only 3% of the English 
population is of Afro-Caribbean ethnicity, and the propor-
tion is lower in the older age group of this study.23
To be pragmatic, we quantified testing for all patients 
against the NICE heart failure practical guidelines, 
although not all patients will have had heart failure as the 
indication for treatment. We chose not to limit to patients 
coded to have heart failure because comorbidity coding 
may not be complete, because coding may be related to 
routine care received24 and also because there is a growing 
evidence base for use of AA in resistant hypertension.2 In 
addition, even for those with coded heart failure, we did 
not have details of patient’s echocardiographic findings 
so could not restrict to those with impaired left ventric-
ular function, although this is the group in whom the 
benefits of treatment despite the risk of worsening renal 
function are clearest.25
A strength of our study is that as well as examining 
the biochemical values of concern noted in the current 
NICE practical guidelines for heart failure, we also 
assessed the incidence of a ≥30% increase in creatinine 
after initiation of AA. This outcome is clinically familiar 
from monitoring after ACEI/ARB initiation but is not 
discussed in the practical guidelines as a parameter in 
the benefit/risk evaluation of continuing AA therapy. 
The clinical significance of such deteriorations in this 
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context is not clear and may indicate favourable haemo-
dynamic changes associated with improved outcomes.6 
However, worsening of renal function has been shown 
to have prognostic significance after initiation of ACEI/
ARB treatment,26 particularly in the context of heart 
failure with preserved ejection fraction.25
comparison with other studies
In a study of patients with heart failure receiving health-
care through the Veterans Affairs health insurance 
programme in the USA between 2003 and 2013, blood 
testing was carried out in 42% of patients within 2 weeks 
of initiation of AA.10 Two other studies of patients with 
heart failure carried out in North American settings 
found slightly higher monitoring rates for AA initi-
ators; 53.5% within 7 days of initiation3 and 44.6% 
within 10 days of initiation.11 The contrast between our 
results and the results of North American research is 
noteworthy because it has been suggested in the past 
that monitoring in the UK is more frequent than in 
Canada.4 9 However, prior research on the frequency of 
monitoring in the UK was carried out in one geograph-
ical area and did not directly assess concordance with 
guideline-recommended testing.9
Previous research examining patient characteristics 
associated with blood testing within 13 months of AA 
initiation found similar results to our study; that males, 
older patients and those with CKD had higher odds of 
receiving blood tests.27 While diabetes was weakly asso-
ciated with testing in our study (OR 1.2 in sensitivity 
analysis of non-hospitalised patients), the association 
was less pronounced than in prior research (OR 1.6).27
We found that 2% of those initiating an AA experi-
enced hyperkalaemia (potassium ≥6 mmol/L) on the 
first blood testing event within 2 months of AA initia-
tion. This compares to a rate of 2% found in Random-
ized Aldactone Evaluation Study and 5.5% in the 
Eplerenone Post–Acute Myocardial Infarction Heart 
Failure Efficacy and Survival Study, both clinical trials 
of AA in patients with heart failure.1 28 In observational 
studies, rates of hyperkalaemia ranging from 6%29 to 
10%30 have been reported. Such populations are said 
to be more reflective of the typical user of AA in clin-
ical practice than in clinical trials, and thus, the rates 
are thought to be more realistic.4 The disparity between 
our results for hyperkalaemia and those found in 
other observational research may have stemmed from 
unknown rates of adherence in this unselected popula-
tion, from differences in doses used6 or from differences 
in methodology. For example, we analysed potassium 
values only on the first blood test within 2 months, 
whereas prior studies examined peak potassium values 
within 3 months of initiation29 and peak values within 
the individuals’ entire treatment period.30 As time since 
initiation increases, it is increasingly likely that blood 
tests in primary care are performed due to an intercur-
rent illness or other event that may itself have contrib-
uted to hyperkalaemia or reduced renal function. Thus, 
we opted to look at the first blood testing event within 
2 months to examine as much as possible a causal asso-
ciation between the initiation of AA and the adverse 
biochemical value. In line with previous literature, we 
found that baseline potassium value was a significant 
predictor of hyperkalaemia after initiation of AA28 29 31 
as was reduced renal function.27–29
As currently referenced in some guidelines 
(online supplementary table 1), using a threshold creat-
inine value as a safety indicator for renal function may 
not be an optimal measure given that absolute creat-
inine levels create an age, gender and ethnicity bias. 
Importantly we found that, consistent with a lower 
muscle mass, women had a lower odds of developing a 
creatinine ≥220 µmol/L initiation of AA in comparison 
to men, but a 1.5-fold higher odds of a ≥30% increase 
in creatinine. The clinical implications of higher odds 
of ≥30% increase in creatinine are unknown, but it is 
important to establish that there is not a discrepancy 
in related clinical outcomes. However, gender-related 
differences in adverse biochemical values were not a 
prespecified hypothesis so this finding must be consid-
ered hypothesis-generating.
cOnclusIOns And clInIcAl IMPlIcAtIOns
We found that among patients prescribed an ACEI/
ARB, less than one-third of those initiating an AA 
received follow-up blood tests within 2 weeks and less 
than two-thirds within 2 months. Approximately 2% 
of patients developed potassium ≥6 mmol/L or creati-
nine ≥220 µmol/L on the first blood test within 2 months, 
but 13.5% experienced a ≥30% increase in creatinine 
from baseline. Women had almost 50% higher odds of 
a ≥30% increase in creatinine than men. Baseline potas-
sium levels >5.0 mmol/L and baseline eGFR categories 
<60 ml/min/1.73 m2 were independently associated 
with a potassium value ≥6 mmol/L after AA initiation. 
Our results highlight the need for better adherence to 
monitoring guidelines, particularly for those in these 
high-risk groups and the importance of understanding 
the prognostic implications of changes in renal func-
tion after AA initiation.
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